The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Improving Radiotherapy Responses in Head and Neck Cancer With Galectin-1

Dhanya K. Nambiar, PhD
Published Online:3:25 PM, Fri May 26, 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses a study exploring galectin-1 in combination with radiation and immune checkpoint therapy in head and neck cancers. 
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.